Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT®-Tc), a totally human monoclonal antibody: Patient management benefit from a phase III multicenter study

Diseases of the Colon and Rectum

Volumn 41, Issue 8, 1998, Pages 953-962

  Wolff, Bruce G ^a   Bolton, John ^b   Baum, Richard ^c   Chetanneau, Alain ^d   Pecking, Alain ^e   Serafini, Aldo N ^f   Fischman, Alan J ^g   Hoover Jr , Herbert C ^h   Klein, Jerry L ⁱ   Wynant, Gordon E ⁱ   Subramanian, Ramaswamy ⁱ   Goroff, Diana K ⁱ   Hanna Jr , Michael G ⁱ  

^a MAYO CLINIC   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h LEHIGH VALLEY HOSPITAL   (United States)

ⁱ Intracel Corp   (United States)

Author keywords

88BV59; Colorectal cancer; Human monoclonal antibody; HumaSPECT Tc; Monoclonal antibody imaging; Technetium

Indexed keywords

HUMASPECT TC; MONOCLONAL ANTIBODY; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ARTICLE; CANCER RECURRENCE; CANCER SCINTISCANNING; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; OCCULT CANCER; PHASE 3 CLINICAL TRIAL; PREOPERATIVE EVALUATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNODETECTION; SAFETY; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY COUNTING;

EID: 0031824063     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02237380     Document Type: Article

References (22)

1. Cancer Facts & Figures - 1996. New York: American Cancer Society, Inc., 1996.
2. Haller DG. Monoclonal antibody imaging in the management of patients with colorectal cancer. J Clin Oncol 1988;6:213-1215.
3. Goldenberg DM, Goldenberg H, Sharkey RM, et al. Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 1989;19:262-81.
4. Larson NM. Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. Radiology 1987;165:297-304.
5. Steele G Jr. Follow-up plans after treatment of primary colon and rectal cancer. World J Surg 1991;15:583-8.
6. Quentmeir A, Schlag P, Smok M. Re-operation for recurrent colorectal cancer: the importance of early diagnosis for resectability and survival. Eur J Surg Oncol 1990;16:319-25.
7. Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174: 27-32.
8. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989;7:1447-56.
9. Cohen AM, Shank B, Friedman MA. Colorectal cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. JB Lippincott: Philadelphia, 1989:895-964.
10. Turk PS, Wanebo HJ. Results of surgical treatment of nonhepatic recurrence of colorectal carcinoma. Cancer 1993;17:4267-77.
11. Cady B, Stone MD. The role of surgical resection of liver metastases in colorectal carcinoma. Semin Oncol 1991; 17:399-406.
12. Beatty JD, Hyams DM, Morton BA, et al. Impact of radiolabeled antibody imaging on management of colorectal cancer. Am J Surg 1989;157:13-9.
13. Haller DG. Monoclonal antibody imaging in the management of patients with colorectal cancer. J Clin Oncol 1988;6:1213-5.
14. Goldenberg DM, Goldenberg H, Sharkey RM, et al. Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Bucl Med 1989;19:262-281.
15. Moffat FL, Vargas-Cuba RD, Serafini AN, et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J Nucl Med 1995;36:738-45.
16. Dejager RL, McCabe RP, Subramian MR, et al. Radioimmunodetection of colorectal carcinoma with technetium-99m labeled human IgG monoclonal antibody 88BV59-1: a Phase I clinical trial. Proc Am Assoc Cancer Res 1991;32:184.
17. Gulec SA, Serafini AN, Moffat FL, et al. Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. Cancer Res 1995;55(Suppl):5774s-6s.
18. Mojiminiyi SA, Shepstone BJ, Soper ND. Human antimurine antibodies (HAMA) in vivo complex formation and the outcome of immunoscintigraphy. J Nucl Med 1990;31:381-2.
19. Price T, Beatty BG, McNally AJ. Human anti-murine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay. Clin Chem 1991;37:51-7.
20. Hansen HJ, Sullivan CL, Sharkey RM, Goldenberg DM. HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassay 1993;16:294-9.
21. Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179-86.
22. Moffat FL, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal Phase III trial. J Clin Oncol 1996;14:2295-305.